Trial Profile

A Phase I, Randomized, Double Blind, Placebo Controlled 2-Parts Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD4205 Following Single and Multiple Ascending Dose in Healthy Adult Subjects, and to Assess the Effect of Food on the Pharmacokinetics of AZD4205

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Golidocitinib (Primary)
Indications Autoimmune disorders; Inflammatory bowel diseases; Non-small cell lung cancer; Peripheral T-cell lymphoma
Focus Adverse reactions
Acronyms JACKPOT2
Sponsors Dizal Pharmaceutical

06 Feb 2020 Status changed from active, no longer recruiting to completed.
28 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jan 2020.
27 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com